Glucose transporters in the small intestine in health and disease
Important context for emerging research: GLP-1 research may eventually inform future understanding of overlapping reward pathways Current evidence does not support GLP-1s as a treatment for co-occurring conditions GLP-1 medications are not part of existing evidence-based treatment pathways At this time, specialized, integrated care remains the standard for treating co-occurring eating disorders and substance use disorders
Quality control of preprocessed data can also be visualized using a range of SpaMTP plotting functions
Personalized Obesity Care Medication, ESG, gastric balloons, and combination care may each have a role depending on the individual patient
At ArtMedica, Dr
Step 3: Choose a Treatment Youll then choose how to move forward with treatment, either paying out of pocket, using insurance for brand-name GLP-1s with prior authorization support, or exploring the best option for your needs based on your providers guidance